Oncolytic Viruses Platform
SATOR Therapeutics has developed a library of nearly 30 oncolytic viruses which have demonstrated a differential response across multiple cancers where several viruses have shown efficacy across multiple indications. The viruses are non-engineered, non-pathogenic and can be administered systemically via IV. These viruses were collected over decades of research and by combining them can overcome many of the challenges associated with a single oncolytic virus and neutralizing antibodies while avoiding the safety problems associated with engineered viruses. Additionally, SATOR has developed a diagnostic approach for predicting efficacy as well as a next-generation delivery approach using dendritic cells.
In Vitro Screening Data
The SATOR viruses have been extensively screened across multiple cancers (mesothelioma, breast cancer, ovarian cancer, glioblastoma and bladder cancer) and it has been demonstrated that they have a differential response with several viruses being highly effective and safe across multiple cancers.
Animal Xenograft Data
SATOR has demonstrated through xenograft mouse model studies with its lead indication of Mesothelioma that the lead virus STR-0011 significantly reduces tumor progression and outperforms T-Vec.
Clinical Safety and Efficacy Data
Through compassionate use studies conducted abroad with over 100 Stage IV patients, the viruses were able to increase overall survival on average >10 months across multiple cancers and in some cases patients were cancer free for several years. Throughout these studies the only adverse effect noted was mild fever. Several of the SATOR viruses were also tested in the 1960's as part of a viral interference project abroad to prevent influenza infection and it was demonstrated with tens of thousands of patients that several of the SATOR viruses were safe with zero adverse effects.
Diagnostic Gating and Next Generation Delivery
SATOR has developed a preliminary companion diagnostic tool for gating patients to increase the efficacy of viral treatment. Additionally, the company has developed a next generation delivery approach that could be used in future efforts to further evade the neutralizing antibody immune response through loading the virus onto dendritic cells.
